Holen Sie sich die Stockscreener-App
16.41
4.99%
0.78
Vorhandelsmarkt:
16.43
0.02
+0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$15.63
Offen:
$15.68
24-Stunden-Volumen:
5.99M
Relative Volume:
2.23
Marktkapitalisierung:
$3.27B
Einnahmen:
$3.90B
Nettoeinkommen (Verlust:
$-413.00M
KGV:
-7.9275
EPS:
-2.07
Netto-Cashflow:
$365.00M
1W Leistung:
+3.08%
1M Leistung:
+6.84%
6M Leistung:
-15.24%
1J Leistung:
-37.82%
1-Tages-Spanne:
$15.65
$16.49
1-Wochen-Bereich:
$15.54
$16.49
52-Wochen-Spanne:
$12.16
$27.95
Dentsply Sirona Inc Stock (XRAY) Company Profile
Firmenname
Dentsply Sirona Inc
Sektor
Telefon
844-546-3722
Adresse
13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC
Vergleichen Sie XRAY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XRAY
Dentsply Sirona Inc
|
16.41 | 3.17B | 3.90B | -413.00M | 365.00M | -2.07 |
|
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Dentsply Sirona Inc Stock (XRAY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-13 | Herabstufung | Needham | Buy → Hold |
| 2025-02-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-01-23 | Herabstufung | Jefferies | Buy → Hold |
| 2025-01-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-25 | Bestätigt | Needham | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-16 | Eingeleitet | Needham | Buy |
| 2023-11-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-12 | Hochstufung | William Blair | Underperform → Mkt Perform |
| 2022-08-05 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2022-06-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-04-19 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-01-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-08-06 | Bestätigt | Barrington Research | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-02 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-03-02 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-01-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-12-18 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-17 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-10-22 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-06-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-15 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-05-27 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-05-11 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-04-24 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-08 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-04-07 | Herabstufung | Goldman | Buy → Neutral |
| 2020-04-02 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-03-03 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-19 | Bestätigt | Stifel | Buy |
| 2019-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-02 | Hochstufung | Wellington Shields | Hold → Gradually Accumulate |
| 2019-07-26 | Eingeleitet | Evercore ISI | In-line |
| 2019-07-09 | Bestätigt | H.C. Wainwright | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Peer Perform |
Alle ansehen
Dentsply Sirona Inc Aktie (XRAY) Neueste Nachrichten
What analysts say about DENTSPLY SIRONA Inc. stockOutstanding capital returns - jammulinksnews.com
Is DENTSPLY SIRONA Inc. a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
Forecasting The Future: 4 Analyst Projections For Dentsply Sirona - Nasdaq
DENTSPLY SIRONA Inc. Stock Analysis and ForecastBreakout profit opportunities - jammulinksnews.com
Macro Challenges and Soft Demand Muddy Dentsply's Recovery Plan, but Our Positive Outlook Remains - Morningstar
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply - MedTech Dive
Here's Why Dentsply International (XRAY) is a Strong Value Stock - Yahoo.co
Dental Implants and Prosthetics Market is projected to reach US$ - openPR.com
What drives DENTSPLY SIRONA Inc. stock priceRemarkably fast returns - jammulinksnews.com
Dentsply Sirona names Daniel Scavilla as new CEO - Dental Tribune US
Dental Equipment Market is projected to reach US$ 12.4 billion - openPR.com
Dental Burs Market Gains Momentum in Aesthetic Dentistry - openPR.com
DENTSPLY SIRONA's Cautious Outlook Amid Leadership Transition and Limited Growth Potential - AInvest
Globus Medical CEO leaves for Dentsply Sirona corner office - MassDevice
Dentsply Sirona names Daniel Scavilla as new CEO, reaffirms 2025 outlook - MSN
Dentsply Sirona (XRAY) Stock Is Up, What You Need To Know - Yahoo Finance
DENTSPLY SIRONA's Leadership Transition and Strategic Reinvigoration: A Catalyst for Long-Term Value Creation - AInvest
Daniel Scavilla Named CEO of Dentsply Sirona - Dentistry Today
Dentsply Sirona Names New CEO And Beats Expectations - Finimize
Dentsply Sirona Hires Globus CEO Dan Scavilla as Chief Exec - Medical Product Outsourcing
Dentsply Sirona names Daniel Scavilla as new CEO effective August 1 - Investing.com India
Dentsply Sirona Appoints Daniel Scavilla as President and CEO, Effective August 1, 2025 - Quiver Quantitative
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer - GlobeNewswire
Former Globus Medical CEO Takes Helm at Dentsply Sirona as Q2 Sales Hit $935M - Stock Titan
Lobbying Update: $80,000 of DENTSPLY SIRONA INC. lobbying was just disclosed - Quiver Quantitative
Are Investors Undervaluing Dentsply Sirona (XRAY) Right Now? - Yahoo Finance
Dentsply Sirona introduces the CEREC Cercon 4D - Dental Tribune US
Dental Implants Market is projected to reach approximately USD - openPR.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 27, 2025 in Dentsply Sirona Inc. LawsuitXRAY - ACCESS Newswire
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now - Yahoo Finance
Dana Carvey, Sheryl Crow and Ellen Latham to headline DS World Las Vegas 2025 - Oral Health Group
Dentsply Sirona’s (XRAY) Long Road to Recovery Amid Economic Challenges - MSN
Tooth Regeneration Market Expands with Advancements - openPR.com
Dental 3D Printing Market Forecast Study 2025, with Leading Dental Companies and Innovators BEGO, Dentsply Sirona, WhipMix, Straumann, Ivoclar, Formlabs, SprintRay, Asiga, and Shining3D - Yahoo Finance
Finanzdaten der Dentsply Sirona Inc-Aktie (XRAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):